About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, November 28th, 2012

The QualityStocks
Daily Stock List


VirTra Systems, Inc. (VTSI)

AllPennyStocks reported earlier on VirTra Systems, Inc. (VTSI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Tempe, Arizona, VirTra Systems, Inc. is a worldwide provider of small arms simulators. The Company offers a variety of simulator platforms, powerful gas-powered recoil kits, as well as the patented Threat-Fire™ simulated hostile return fire system. VirTra Systems develops, sells, and supports judgment and marksmanship firearms training systems for law enforcement, military, or civilian use around the world. Founded in 1993 (they began as Ferris Productions, which opened for business in May 1993), the Company lists on the OTC Pink Current Information.

VirTra Systems has been an industry leader in the simulation and virtual reality marketplace for nearly twenty years. The Company's primary focus is the sale and support of the world's finest firearms training simulators.

Concerning Military Training, VirTra Systems offers a full line of firearms training and combat simulators. They offer portable single-screen simulators all the way up to the world's most challenging and advanced combat training simulator – the VirTra 300 MIL. The VirTra 300 MIL is the world's only 5 screen decision-making and tactical firearms training simulator.

Concerning Law Enforcement Training, VirTra Systems offers a full line of judgmental-use-of-force training simulators along with full firearms training capability. The Company offers portable single-screen simulators all the way up to the most challenging and advanced use-of-force simulator in the world – the VirTra 300 LE. The VirTra 300 LE is the world's only 5 screen judgmental use-of-force training simulator.

In addition, another product the Company offers is the VirTra Range. The VirTra Range LE (Patent-Pending) is a realistic and detailed shooting range simulator. Furthermore, VirTra offers the aforementioned Threat-Fire™. This product enhances training effectiveness by delivering an adjustable electric impulse simulating hostile return fire. The standard setting of just 30 milliseconds of electric impulse is enough to add real-world consequences that significantly enhance the effectiveness of simulation training.

This month, VirTra Systems reported unaudited financial results for their third quarter ended September 30 2012. The Company reported revenue of $1.42 million and a net loss of $0.63 million. Through three quarters of the year, the Company has realized $6.96 million of revenue and $0.22 million of net income; this exceeds 2011 results on a pro rata basis.

VirTra Systems, Inc. (VTSI), closed Wednesday's trading session at $0.048, down 4.00%, on 17,500 volume with 2 trades. The average volume for the last 60 days is 79,006 and the stock's 52-week low/high is $0.04/$0.09.

Cono Italiano, Inc. (CNOZ)

SizzlingStockPicks reported recently on Cono Italiano, Inc. (CNOZ), Stock Alerts, ChartAdvisor, InsideBulls did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Keyport, New Jersey, Cono Italiano, Inc.'s mission is to be the world's leading consumer products company for foods "On the Go" and "fast foods." The Company holds license rights to manufacture, market, and distribute Pizza Cono, a cone-shaped pizza, in the United States, Canada, and Mexico. Mitchell Brown - Company President and Chief Operating Officer - founded Cono Italiano in 2007. The Company lists on the OTC Markets: OTCQB.

The Pizza Cono began in Milan, Italy in 2001 where SpuntiBreak S.R.L founder Mr. Marco Messuti created the "Pizza Cono". This product is a cone made of dough from proprietary ingredients and filled with cheese and sauce to be consumed while "on the go." The Pizza Cono can be filled with any number and variety of ingredients.

Cono Italiano manufactures and distributes the Pizza Cono throughout the U.S., Canada and Mexico. The Pizza Cono product can be prepared by baking in a conventional oven, microwave and the "Tornado" by Turbochef. The cone is being distributed into quick service restaurants (QSRs) and leisure locations including convenience stores, supermarkets, entertainment facilities and sports arenas. Cono Italiano is currently producing their Par-Baked Drip-free bottom cones at Sunrise Bakery in Brooklyn, New York.

On September 7, 2011, Cono Italiano entered into a strategic manufacturing agreement with Interstate Caterers. The Company continues advancing forward with the production of their frozen foods and Pizza Cono. Moreover, they added empanadas to their product family. Cono Italiano plans to fund the manufacturing process of these products via the use of private funding investors and resources from Interstate Caterers.

In the first quarter of 2012, the Company added a fully automated filling machine to fill their Pizza Cono with a variety of flavors. During the next 12 months, they plan to start the international distribution of their Pizza Cono and empanadas in the United Kingdom (contract with Spuntibreak s.r.l), Canada and the U.S.

Cono Italiano's plan is to distribute their products through using independent sales representatives, food and wholesale distributors, as well as employees. The Company anticipates developing their own proprietary microwave packaging and microwave sleeves for their products. They acquired the Flo Pack, a packaging machine to assist in their retail distribution and shipping. The Flo Pack is operational and the Company will sell their product using the Flo Pack during this 4th quarter and going forward.

Cono Italiano, Inc. (CNOZ), closed Wednesday's trading session at $0.031, up 18.77%, on 27,967 volume with 11 trades. The average volume for the last 60 days is 94,068 and the stock's 52-week low/high is $0.02/$0.096.

MultiCell Technologies, Inc. (MCET)

PennyTrader Publisher, OTCPicks, StockHideout, Greenbackers, Penny Stock Rumble, and HotShotStocks reported earlier on MultiCell Technologies, Inc. (MCET), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company whose shares trade on the OTCQB. The Company is developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. Their portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development. MultiCell Technologies has their headquarters in Woonsocket, Rhode Island. Xenogenics Corp. is a subsidiary of MultiCell Technologies.

The Company's therapeutic development platform relies on several patented technologies. These are used to isolate, characterize and differentiate stem cells from human liver, or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or modulate the noradrenaline-adrenaline neurotransmitter pathway.

MultiCell Technologies' portfolio of lead drug candidates includes MCT-125, MCT-465, MCT-475, and MCT-485. MCT-125 is a Phase 2 therapeutic candidate for the treatment of PMSF. It has demonstrated efficacy in a 138 patient Phase IIa clinical trial. MCT-465 is a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

MCT-475 is a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers. Furthermore, the Company sells a range of life science research reagents. These reagents facilitate the discovery and development of new therapies and diagnostic tests.

In September, MultiCell Technologies announced the acceptance by the American Society for Cell Biology® (ASCB®) of abstract "Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma."  Anand Ghanekar M.D., Ph.D., Division of Cellular & Molecular Biology, Toronto General Hospital Research Institute, will present the preclinical research results at the 2012 ASCB Annual Meeting in San Francisco, California, December 15-19, 2012.

Recently, MultiCell Technologies announced that they added Mr. Grant G. Miller to their Board of Directors. Mr. Miller will replace Mr. Altig who will be stepping down to allow for this appointment. Mr. Miller currently serves as Chief Financial & Operating Officer of Sandel Avionics.

MultiCell Technologies, Inc. (MCET), closed Wednesday's trading session at $0.0012, up 9.09%, on 867,900 volume with 5 trades. The average volume for the last 60 days is 10,823,628 and the stock's 52-week low/high is $0.001/$0.0075.


Wallstreetlivechat reported yesterday on ANADIGICS, Inc. (ANAD), StreetInsider, Penny Detectives, CrushTheStreet.com, MonsterStocksPicks, Stock Stars did earlier, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

ANADIGICS, Inc. provides semiconductor solutions to the broadband wireless and wireline communications markets. The Company delivers integrated radio frequency (RF) solutions that OEMs and ODMs demand to optimize the performance of wireless, broadband and cable applications across all major networks and standards. The Company pioneered the high volume cost-effective manufacture of high performance gallium arsenide integrated circuits (GaAs ICs). ANADIGICS has their corporate headquarters in Warren, New Jersey. Founded in 1985, the Company lists on the NASDAQ Global Select market.  

ANADIGICS features a varied portfolio of highly linear, highly efficient radio frequency integrated circuits (RFICs). Their award-winning products include power amplifiers, tuner integrated circuits, active splitters, line amplifiers and other components that a customer can purchase individually or have packaged as integrated RF and front-end modules.

The Company's high frequency RFICs enables manufacturers of communications equipment to enhance overall system performance. This is through reducing the size and weight of their products, increasing power efficiency, improving reliability, and reducing manufacturing cost and time to market. ANADIGICS' 6-inch GaAs manufacturing facility utilizes state-of-the-art technology and manufacturing processes to deliver high quality InGaP HBT, GaAs MESFET, and GaAs pHEMT RFIC products.

Yesterday, ANADIGICS introduced the AWB7129 small-cell power amplifier (PA).  The optimization of the AWB7129 is for Band 8 WCDMA and LTE applications. This includes picocells, enterprise-class femtocells, and high performance customer premises equipment (CPE).  The small-cell wireless infrastructure power amplifiers take advantage of ANADIGICS patented InGaP-Plus™ technology and unique design architectures to deliver best-in-class efficiency, linearity and thermal characteristics.

The optimization of the AWB7129 small-cell power amplifier is for WCDMA, HSPA, and LTE small-cell base stations operating in the 925 MHz to 960 MHz frequency band.  The power amplifier delivers 15 percent efficiency to minimize power requirements. The AWB7129 has linearity of -47 dBc ACPR @ +/- 10 MHz offset, +24.5 dBm linear output power, and 30 dB gain. The AWB7129 is optimized to provide high throughput data rates with a broad coverage area.  The AWB7129 small-cell PA is provided in a compact, low profile 7 mm x 7 mm x 1.3 mm surface mount package with integrated RF matching to reduce PCB space requirements.

ANADIGICS, Inc. (ANAD), closed Wednesday's trading session at $1.71, up 14.00%, on 1,310,904 volume with 4,285 trades. The average volume for the last 60 days is 386,443 and the stock's 52-week low/high is $1.05/$3.22.

Kivalliq Energy Corp. (KIV.V)

AllPennyStocks reported previously on Kivalliq Energy Corp. (KIV.V), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Kivalliq Energy Corp. is a uranium exploration company whose shares trade on the TSX Venture Exchange. The Company holds Canada's highest-grade uranium deposit outside of Saskatchewan's Athabasca Basin. Kivalliq Energy was the first company to sign a comprehensive agreement to explore for uranium on Inuit Owned Lands in Nunavut Territory. For Kivalliq, this means they have a 100 percent interest in the Lac Cinquante property (IOL-RI30). Kivalliq Energy has their corporate headquarters in Vancouver, British Columbia.

Kivalliq Energy's flagship project is the 252,830-acre Angilak Property in Nunavut Territory. Kivalliq's team of northern exploration specialists have established strong relationships with sophisticated resource sector investors and project partner Nunavut Tunngavik, Inc. (NTI) to advance the Angilak Property.

The Angilak Property is host to the Lac Cinquante Deposit with an NI 43-101 Inferred Resource of 1,779,000 tonnes grading 0.69 percent U3O8, totaling 27.13 million pounds U3O8. The Company's comprehensive exploration programs continue to advance the Lac Cinquante Deposit and demonstrate the "District Scale" potential of the Angilak Property.

The Angilak Property hosts a number of high priority zones. Since acquiring the Angilak Property in 2008, Kivalliq Energy has invested approximately $50 million conducting systematic exploration. This includes ground and airborne geophysics, geological mapping; prospecting, and more than 87,500 meters of diamond and reverse circulation (RC) drilling.

Yesterday, Kivalliq Energy announced results from 80 diamond drill holes from within the Lac 50 Trend. This includes high-grade uranium assays from the J4 Zone. The J4 Zone (discovered on July 1, 2012) is approximately two kilometers southeast of the Lac Cinquante Uranium Deposit. It is one of five mineralized zones discovered this year within the Angilak Property in Nunavut. Final results have now been reported from drilling within the Lac 50 Trend in 2012.

Kivalliq Energy's President, Mr. Jeff Ward, stated, "This year's drilling at J4 Zone has returned assay results with both high grades, and now with Hole J4-12-050, broad intervals of uranium mineralization. We look forward to incorporating results from this significant 2012 discovery into a revised resource estimate, scheduled for early 2013."

Drilling at J4 intersected uranium over a strike length of 800 meters and; to a vertical depth of 383 meters, the deepest uranium intercept on the Angilak Property to date.

Kivalliq Energy Corp. (KIV.V), closed Wednesday's trading session at $0.285, down 10.94%, on 1,321,650 volume. The stock's 52-week low/high is $0.31/$0.64.

Auxilio, Inc. (AUXO)

MicroCap Gems, Tiny Gems, MissionIR, OTCPicks, and SmallCapVoice reported earlier on Auxilio, Inc. (AUXO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Auxilio, Inc.'s dedication is to uncovering hidden costs and improving processes in managed print services for hospitals. The Company is the pioneer of managed print services for the health care industry, working exclusively with hospitals and hospital systems throughout the United States. Auxilio is vendor independent and provides intelligent solutions, a risk free program, and guaranteed savings. The Company lists on the OTCQB. Auxilio is based in Mission Viejo, California.

Auxilio is a Managed Print Services Company (MPS). A true MPS that does not sell equipment enables organizations to reduce the cost and improve the processes associated with printing and copying documents. This is through managing, monitoring and measuring everything associated with that infrastructure. Auxilio is the first and still the only MPS across the nation that works exclusively within the health care industry and hospitals. They transform print environments in hospitals and guarantee upwards of 30 percent in savings to maximize productivity and minimize costs.

The Company assumes all costs related to print business environments by way of customized, streamlined and seamless integration of services at predictable fixed rates. They work collaboratively to assist their health care-partners in the delivery of quality patient care. The Company's on-site Centers of Excellence professional print strategy consultants deliver service and solutions.

This month, Auxilio announced a new five-year contract with LRGHealthcare in New Hampshire to implement their Managed Print Services program in the care organization's Lake's Region General Hospital and Franklin Regional Hospital. LRGHealthcare is the second hospital group affiliated with the Granite Healthcare Network (GHN), a partnership of five independent New Hampshire charitable organizations, to contract with Auxilio.

In addition, this month, Auxilio announced their financial results for the quarter ended September 30, 2012. For the three months ended September 30, 2012, they reported net revenue of $8.8 million. This represents an increase of 31 percent compared to $6.7 million in the same period of 2011.

Gross profit for the third quarter of 2012 was $1.4 million, or 15 percent of sales. This is in comparison to $1.3 million, or 19 percent of sales in the third quarter of 2011. Operating expenses were $1.7 million for the third quarter of 2012, or 19 percent of sales, compared to $1.3 million, or 19 percent of sales, in the same quarter of 2011. Net loss for the quarter was $660,000, or $0.03 per share. This is in comparison to a net loss of $47,000, or $0.00 per share, in the third quarter of 2011.

Auxilio, Inc. (AUXO), closed Wednesday's trading session at $0.93, up 9.41%, on 28,600 volume with 11 trades. The average volume for the last 60 days is 9,864 and the stock's 52-week low/high is $0.70/$1.47.

VersaPay Corp. (VPY.V)

We are reporting on VersaPay Corp. (VPY.V), here at the QualityStocks Daily Newsletter.

VersaPay Corp. is a provider of merchant credit and debit card payment processing and electronic money transfer (EMT) and electronic invoice presentment and payment (EIPP) solutions. The Company's financial technology enables businesses and consumers across Canada to accept and process credit, debit and gift card transactions. The Company serves more than 2,500 Canadian businesses. VersaPay has their headquarters in Toronto, Ontario and has operations in Montreal, Quebec, Vancouver, British Columbia, and New York, New York. Founded in Vancouver in 2005, VersaPay went public on January 20, 2010 on the TSX Venture Exchange.

VersaPay, together with their partners, provides the hardware; technology; infrastructure, and support services that businesses of all kinds need to accept and process electronic payments from their consumers and clients. The Company's core business is payment processing services. However, VersaPay also provides enhanced financial technology solutions including VersaPay EMT - their proprietary Electronic Bill Presentment and Payment solution that enables merchants and consumers to transact easily with one another. VersaPay is partnered with Chase Paymentech in Canada.

Earlier this month, VersaPay announced that they entered into a strategic alliance agreement with MasterCard International, Inc. VersaPay and MasterCard will collaborate to increase usage of MasterCard's products on VersaPay's EIPP platform in Canada.

Yesterday, VersaPay announced their financial and operational results for the three and nine month ended September 30, 2012. Total revenues for Q3 2012 increased 7 percent to $4.6 million from $4.3 million in Q3 2011. Of this amount, recurring revenues for Q3 2012 increased 8 percent to $4.6 million from $4.2 million in Q3 2011. Total revenue for the nine months ended September 30, 2012 increased 12 percent to $12.7 million from $11.4 million for the same period in 2011. Of this amount, recurring revenues for the nine months ended September 30, 2012 increased 13 percent to $12.7 million from $11.1 million in 2011.

Adjusted EBITDA for Q3 2012 was $(0.09) million, compared to $0.1 million in Q3 2011. For the nine months ended September 30, 2012, Adjusted EBITDA was $(0.6) million, in comparison to $(0.2) million in 2011. Loss from continuing operations for Q3 2012 was $(0.2) million. This compares to an income from continuing operations of $0.01 million for Q3 2011. For the nine months ended September 30, 2012, loss from continuing operations was $(1.0) million, in comparison to $(0.6) million in 2011.

VersaPay Corp. (VPY.V), closed Wednesday's trading session at $1.40, even for the day. The stock's 52-week low/high is $0.80/$1.40.

Castillian Resources Corp. (CTIIF)

We are reporting on Castillian Resources Corp. (CTIIF), here at the QualityStocks Daily Newsletter.

Castillian Resources Corp. is a mineral exploration company whose shares trade on the OTCQX International. The Company has gold and base metal properties in Canada and South America. Castillian's flagship property is the Hope Brook Gold Project located in southwestern Newfoundland. Castillian Resources is headquartered in Toronto, Ontario. The Company also lists on the TSX Venture Exchange under the symbol "CT".

At their flagship Hope Brook Gold Project, Castillian is carrying out a 25,000-meter diamond drill program. The Hope Brook Gold Project has 2.4 million tonnes at 1.48 g Au/t for 590,000 ounces of NI 43-101 compliant indicated mineral resources and 8.2 million tonnes at 2.07 g Au/t for 548,000 ounces of inferred mineral resources.

At the Hope Brook Gold Project, the deposit is open along strike and at depth with several target areas already defined. The Company believes there is excellent potential to expand the resource. Castillian has an option to purchase 100 percent interest in 993 claims covering approximately 25,000 ha. There was historical production of 752,163 ounces of gold during the period of low gold prices (1987-1997).

Castillian Resources has outlined an extensive new Gold-in-Soil anomaly trend on their Canadian Creek Gold Project in the Yukon, adjacent to Kaminak's Sugar Gold-in-Soil trend. Drilling by previous operators has confirmed significant gold mineralization including 0.72 g Au/t over 55.3m. The significant new gold-in-soil anomaly, the Canadian Creek trend, is 7.5 kilometers long by 2 kilometers wide.

A major structural zone, greater than 10 kilometers along strike, is sub-parallel to the gold-in-soil trend. The highest new gold-in-soil value within the Canadian Creek trend is 0.97 g Au/t, with historic gold-in-soil values up to 2.29 g Au/t.

This month, Castillian Resources announced that they sold their block of 5,000,000 ordinary shares in Kibaran Resources Ltd. for gross proceeds of approximately AUD 540,000. Castillian's intention is to use these funds for working capital purposes. The Kibaran shares were issued to Castillian in consideration for the sale of the Kagera Nickel Sulphide Project to Kibaran in 2010.

Castillian Resources Corp. (CTIIF), closed Wednesday's trading session at $0.25, even for the day, on 10,000 volume with 1 trades. The average volume for the last 60 days is 11,195 and the stock's 52-week low/high is $0.06/$0.75.


The QualityStocks
Company Corner


The Guitammer Company Inc. (GTMM)

The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.23, off by 4.17%, on 12,600 volume with 2 trades. The stock’s average daily volume over the past 60 days is 9,805, and its 52-week low/high is $0.082/$0.35.

The Guitammer Company Inc. reported on recent open market purchases of shares by the company's CEO, CFO, and Director (Mark A. Luden, 100k shares; Rich E. Conn, 4k; Walter J. Doyle, 52k), totaling 156k shares between the 5th and 16th of November and that the associated Form 4 filings are available on the SEC's Edgar site. Luden noted that this was the first opportunity for the trio to complete open market share purchases of this nature as per the company's "insider trading policy" since GTMM hit the OTCBB exchange. Luden further remarked quite warmly about overall confidence in the upward momentum of the company, based not only on year-to-date financial results, but success of the ButtKicker-branded business and potential of the patent-protected ButtKicker LIVE! broadcast technology for generating hearty recurring revenue streams.

The Guitammer Company Inc. (GTMM) is a leader in low-frequency sound products and technology. The company’s award-winning line of patented ButtKicker brand audio transducers let users actually feel the excitement, impacts, special effects, and bone-rattling bass brought by its immersive “4D” patent-protected technology. Guitammer’s products are well known for being musically accurate, powerful, and virtually indestructible.

The Guitammer Company was founded in 1990 by Ken McCaw, an accomplished musician, composer, and producer. Joining forces with Marvin Clamme, former sound engineer for Tom Jones and Merle Haggard, Ken and Marvin developed the original ButtKicker transducer prototypes in 1994.

Today, the ButtKicker brand products are used around the world by leading entertainment and theater companies, including AMC, IMAX, and Disney, in movie theaters and attractions. 85 entertainment locations in 11 countries have incorporated ButtKicker products to-date, providing the ultimate experience to over 10,000 seats. The products are also used in home theaters, simulators, and car audio applications.

Guitammer’s technology is compatible to virtually any digital source, including cable, satellite, fiber optic, IPTV, “over-the-air” broadcast, video games, and audio CDs. The ButtKicker brand products add unparalleled realism and excitement to movies, music, and games. Guitammer’s low-frequency, high-impact sound innovation is the next logical step after HDTV, 3DTV, and TiVo, bringing ground-breaking changes in how consumers enjoy their entertainment. Disclaimer

The Guitammer Company Inc. Company Blog

The Guitammer Company Inc. News:

Guitammer Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases

Guitammer Third Quarter Revenue More Than Triples To $555,000

Guitammer CEO Mark Luden to Present at 7th Annual Singular Research 'Best of the Uncovereds' Conference in Los Angeles

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would likeup 48.15% to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.012, up 48.15%, on 148,150 volume with 4 trades. The stock’s average daily volume over the past 60 days is 190,414, and its 52-week low/high is $0.001/$0.018.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Files Form 10-K Report With the Securities and Exchange Commission

CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.69, up 6.15%, on 1,300 volume with 2 trades. The stock’s average daily volume over the past 60 days is 969, and its 52-week low/high is $0.06/$3.15.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D

VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions

VistaGen Therapeutics Completes $3.25 Million Financing and $3.0 Million Debt Restructuring

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $8.20, off by 1.20%, on 16,200 volume with 34 trades. The stock’s average daily volume over the past 60 days is 50,191, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC

TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer

The Guitammer Company Inc. (GTMM) Reports Open Market Insider Purchases

The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker® audio transducers, announced today that CEO Mark A. Luden, Chief Financial Officer Rich E. Conn, and Director Walter J. Doyle acquired a collective 156,000 common shares of Guitammer in open market purchases this month. Luden, Conn, and Doyle purchased shares at prices ranging up to $0.35 per share.

“Pursuant to Guitammer’s ‘insider trading policy,’ this represented the first opportunity for Walter, Rich and I to complete open market share purchases since the company began trading on the OTCBB,” stated Mark Luden. “Our collective and growing optimism in Guitammer is based on the financial results the Company has posted year-to-date, noteworthy recent progress across our ButtKicker-branded business as reflected in the increasing global awareness of and demand for our products, and a belief that Guitammer’s patent-protected ButtKicker LIVE!® broadcast technology is moving ever closer to becoming a commercial, recurring revenue-generating reality.”

Today’s news comes on the heels of a press release announcing a 210% increase in third quarter revenue versus the same period a year earlier, in addition to a 189% year-over-year increase in gross profit. Growing popularity of the ButtKicker brand, liquidity capable of supporting continued growth, and the continued development of the company’s patented ButtKicker Live! technology has Guitammer well positioned to further increase shareholder value.

For further information about The Guitammer Company, visit www.guitammer.com, www.thebuttkicker.com, or www.shakemycouch.com

Cardium Therapeutics, Inc. (CXM) Moving Rapidly with Excellagen

Excellagen, Cardium’s FDA-cleared highly-refined fibrillar collagen-based topical gel designed to facilitate wound care management for diabetic ulcers and many other types of wounds, has been the center of much of Cardium’s recent activity. The product was selected by Podiatry Today, an award-winning monthly publication on foot care, as one of the top 10 podiatry innovations in 2012, and is considered a very promising tool for accelerating the wound healing process. Cardium recently announced the formation of a Medical Advisory Board for Excellagen, made up of leading practitioners, clinicians, and researchers with diversified expertise in the field of advanced wound care. The company also announced the publication of an Excellagen “Profiles in Excellence 2012” article in Podiatry Management and two presentations at the Desert Foot 2012 High Risk Diabetic Foot Conference in Phoenix, Arizona.

Excellagen has been the subject of positive findings by physicians actively using Excellagen, with a number of physicians observing a rapid onset of the growth of granulation tissue, an important part of the wound healing process. In certain cases, rapid granulation tissue growth and wound closure have been reported using Excellagen’s wound care management therapy following unsuccessful treatment with other advanced wound care approaches. In addition, remarkable biological healing responses have been observed following cancer-related Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds.

Having received FDA clearance for Excellagen, Cardium has established cGMP out-sourced manufacturing and supply with UK-based Angel Biotechnology. The company has also developed cold chain logistics and distribution with Smith Medial Partners, and initiated a pathway toward securing private payer and government product reimbursement, including Centers for Medicare & Medicaid Services (CMS), and has assembled an internal strategic and tactical sales and marketing team. The company is currently engaged in physician relationship building with key opinion leaders, product sampling, practice integration, and building a portfolio of physician case studies.

Excellagen has been engineered to serve as a delivery platform enabling multiple device and therapeutic product extensions. The company is currently in discussions with strategic partners to establish representation, marketing and sales, or co-promotional arrangements into various U.S. vertical wound healing market channels.

For additional information, visit www.CardiumTHX.com

TNI BioTech, Inc. (TNIB) and Immunotherapy

Just as stem cell technology holds out the current best hope for the regeneration of healthy cells, immunotherapy is becoming the latest best hope for efficiently dealing with diseased cells. Although immunotherapy in its broadest form can be said to date back to the pioneering work of 18th century English physician Edward Jenner, who greatly advanced the ancient but dangerous practice of inoculation, the modern practice of manipulating the body’s own immune system to treat disease is often marked by American surgeon William Coley who developed a rudimentary cancer treatment based on provoking an immune response to bacteria around 1891.

Today, although it is still a developing science, immunotherapy has become an important tool for treating various types of cancer, as well as other diseases. It can be used to provide a general boost to the body’s immune system, or can be used to focus the immune response against specific types of cancer cells. In addition, immunotherapy can be used to suppress certain immune system reactions, which is important for preventing rejection of organ transplants or for treating various auto-immune diseases.

TNI BioTech is a Maryland based biotechnology company that uses their own patented immunotherapy technology to mobilize the body’s immune system and combat fatal diseases, including cancer and infectious diseases such as HIV/AIDS. The company’s most advanced clinical program works by isolating a patient’s lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. The lymphocytes are then put back into the patient to destroy tumor cells.

The company is currently working with three primary products:

• IRT-101, an active immunotherapy that works by activating a patient’s immune system against infectious diseases and tumor cells

• IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient’s own immune cells

• IRT-103, an active immunotherapy that works by activating a patient’s immune system against HIV/AIDS and tumor cells

For additional information, visit www.TNIBiotech.com

Vermillion, Inc. (VRML) Appoints Bruce Huebner as Interim CEO

Vermillion, a molecular diagnostics company, announced that director Bruce A. Huebner has been appointed as interim CEO. He is following Gail S. Page, the company’s most recent CEO, who will assist in the transition and serve as a strategic advisor. Mr. Huebner will continue to serve on the board of directors as he assumes his new role.

Mr. Huebner has executive management experience in multiple clinical diagnostic companies, including Osmetech Molecular Diagnostics, Nanogen, and Gen-Probe. While serving as president of Osmetech, he successfully established the company as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace. Huebner was also president and COO of Nanogen, a publicly held nanotechnology and microarray company.

Prior to Nanogen, Mr. Huebner was executive vice president and COO of Gen-Probe, a global leader in the development of nucleic acid tests. In less than 10 years, he grew Gen-Probe’s annual revenues from $42 million to a run-rate of more than $150 million. Huebner is currently a managing director of LynxCom Partners, a healthcare consulting firm with a focus on cancer diagnostics and personalized medicine.

“With more than 37 years of diagnostic industry experience and leadership, as well as serving on a special Vermillion board committee that evaluates marketing strategies for OVA1, Bruce will provide seasoned leadership as our interim CEO,” said James S. Burns, the company’s chairman of the board. “He will actively manage the business and ensure continuity of operations, as our succession committee searches for a new CEO who will take the company to its next level of growth and development.

Burns continued, “I would also like to thank Gail for the leadership and dedication that she has provided in bringing OVA1 to market and a pipeline of products to improve women’s health. We look forward to consulting with Gail in the coming months as we continue to build advocacy for our ovarian cancer franchise among gynecologists and women’s health groups.”

For more information, visit www.vermillion.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251